The safety and efficacy of Strattera in the maintenance of attention-deficit hyperactivity disorder (ADHD) was demonstrated in one of the largest relapse prevention studies ever conducted in ADHD, which is one of the most common mental health disorders in children and adolescents. Strattera provides uninterrupted relief from ADHD symptoms throughout the day into the evening.
Thomas Spencer, associate professor of psychiatry, Harvard Medical School, said: “The approval provides physicians and their patients with the first treatment option that is indicated for maintenance of ADHD. This is critical as ADHD may be a life-long disease and effective long-term control of symptoms may mean improved outcomes in children and adolescents.”